Drug Profile

OC 101 - Oyster Point Pharmaceuticals

Alternative Names: MR-146; OC-101 (AAV-NGF); OC-101 - Oyster Point Pharmaceuticals

Latest Information Update: 02 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Oyster Point Pharmaceuticals
Class Eye disorder therapies; Gene therapies; Nerve growth factors
Mechanism of Action Gene transference; Nerve growth factors replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Neurotrophic keratopathy

Most Recent Events

18 Dec 2025 US FDA approves IND application for MR 146 in Neurotrophic keratopathy
18 Dec 2025 Viatris Inc plans the phase I/II CORVITA trial for Neurotrophic keratopathy (Ophthalmic, Injection), in the first half of 2026
03 Jan 2023 Oyster Point Pharmaceuticals has been acquired by Viatris Inc

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com